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Background: Mozambique implemented artemisinin-based combinations therapy (ACT) using artemether-
lumefantrine (AL) as the first-line treatment for uncomplicated malaria in 2009. AL remains highly efficacious, but
widespread use may soon facilitate emergence of artemisinin tolerance/resistance. The prevalence of pfmdr1
different alleles in Maputo and Mozambique is not known, either after or before the introduction of ACT. Pfmdr1
molecular markers related to Plasmodium falciparum susceptibility were analysed before and after transition to ACT.
Methods: A first group of samples was collected between June 2003 and June 2005 and a second group in the
period between March 2010 and March 2012. Three alleles were analysed by PCR-RFLP: N86Y, Y184F and D1246Y, in
the pfmdr1 gene.
Results: Alleles N86, 184F and D1246 increased from 19.5, 19.6 and 74.4% in 2003–2005 to 73.2, 22.7 and 96.7% in
2010–2012, respectively. After implementation of ACT (2010–2012), pfmdr1 haplotypes, either two- and three-codon
basis, were generally less diverse than before the implementation of ACT (2003–2005). The prevalence of haplotypes
N86-184Y, N86-D1246 and 184Y-D1246 increased from 12,2, 27.3 and 71.7% in 2003–2005 to 59.4, 84.3 and 78.6% in
2010–2012. The three-codon basis haplotypes NFD and NYD also increased significantly during the same period.
Conclusion: The alleles N86 and 184 F and the triple haplotype N86-184 F-D1246 showed a significantly increased
prevalence after introduction of ACT.
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The Plasmodium falciparum multi-drug resistance gene
1 (pfmdr1) and particularly, single nucleotide polymor-
phisms (SNPs) resulting in an amino acid change in co-
dons 86 (N86Y), 184 (Y184F), and 1246 (D1246Y) have
been associated with changes in parasite susceptibility to
various drugs, including artemisinin-based combination
therapy (ACT) [1-4]. Initially, SNPs in pfmdr1 were asso-
ciated with chloroquine (CQ) and amodiaquine (AQ) re-
sistance [5]. For instance, the pfmdr1 86Y mutation has* Correspondence: loboelsa@yahoo.com.br
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unless otherwise stated.been associated with high CQ resistance [6,7], and the
combination of pfmdr1 86Y, Y184, and 1246Y is likely se-
lected by AQ monotherapy and associated with increased
risk of treatment failure [1,2]. Although SNPs at positions
1034 and 1042 of pfmdr1 were described as being related
to phenotype modulation by altering a drug pocket in
PfMDR1 [8], they are very infrequent in Africa.
ACT drug resistance has recently been reported at the
Thai-Cambodian border [9-11]. Historical evidence shows
that the emergence of drug-resistant P. falciparum strains
first originated in Southeast Asia and then, spread to
Africa [12]. East Africa has been a major focus of drug re-
sistance spread, and development in sub-Saharan Africa
[12,13], probably originated at Southeast Asia [13-15].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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may serve as an early warning tool of emerging P. falcip-
arum tolerance/resistance to ACT [16]. Mozambique, an
Eastern Africa country, with a population of 20.2 million,
is amongst the ten most affected countries by malaria in
the world. Here, malaria represents one of the major pub-
lic heath challenges, being responsible for nearly 45% of
registered disease episodes, 56% of cases admitted to
paediatric health facilities and about 26% of deaths in hos-
pitals [17]. During the last decade, African countries have
changed first-line treatment of uncomplicated falcip-
arum malaria to ACT due to the development of resist-
ance to successively introduced anti-malarial drugs.
In Mozambique, CQ was replaced by sulphadoxine-
pyrimethamine (SP) in 2002 (in combination with AQ)
and in 2004 AQ was replaced by artesunate (ATN) in
that combination. Since 2009, this combination was re-
placed by artemether-lumefantrine (AL) [17,18].
Apart from the work of Raman and colleges [19], the
prevalence of pfmdr1 different alleles in Maputo and
Mozambique is still scarce, either after or before the
introduction of ACT. In line with this, molecular markers
related to P. falciparum susceptibility were analysed in




DNA samples included in this study were collected from
patient blood spots obtained at three health facilities in
Maputo area. One study was conducted at Hospital
Central de Maputo, Centro de Saúde de Bagamoio and
Centro de Saúde de Boane between June 2003 and June
2005 and the other at Centro de Saúde de Boane and
Centro de Saúde 1° de Maio between March 2010 and
March 2012. Both studies were reviewed and approved
by the Ethical Committees of the Ministry of Health of
Mozambique and informed consent was obtained at the
time.
Genetic characterization of the parasites
Included samples came from PCR-confirmed P. falciparum
infections [20]. DNA was extracted from filter paper blood
spots using Chelex as described elsewhere [21]. Plasmo-
dium falciparum mutations in pfmdr1 gene were typed by
PCR-RFLP as described elsewhere [21,22], primers se-
quences, amplification cycles and restrictions enzymes for
86Y and 1246Y are described in [21] and for Y184 in [23].
Statistical analysis
Allele and haplotype prevalence in the groups were
compared by Chi-squared tests and, when appropriate,
a residual analysis was performed in order to determine
reasons for the rejection of independency between thevariables under study. Statistical significance was set at
p ≤ 0.05. All calculations were performed with IBM
SPSS 20.0.
Results
In this study, the presence of alleles of the pfmdr1 gene
(codons 86, 184 and 1246) in patients with uncompli-
cated falciparum malaria, before (2003–2005) and after
the implementation of ACT in Maputo area (2010–2012)
were analysed. A total of 133 samples were included in
the group 2003–2005 (only 56 of the 133 samples were
analysed for the codon 184) and 351 in 2010–2012.
The typing efficiency for each codon was as follows:
2003–2005 group, 100% of samples for the N86Y, 100%
for Y184F (only 56 of the 133 samples were analysed)
and 91% for D1246Y; 2003–2005 group, 96.9% of sam-
ples for the N86Y, 99.1% for Y184F and 96.0% for
D1246Y.
The individual prevalence of SNPs at codons 86, 184
and 1246 in 2003–2005 and 2010–2012, including mixed
codon infections, are shown in Figure 1 with Table 1
showing individual SNPs and haplotypes.
To examine for temporal changes in prevalence of SNPs
at codons 86, 184 and 1246, mixed infections (both alleles
present) were analysed together with the polymorphism
not associated with ACT tolerance/resistance, i.e., pfmdr1
86Y, Y184, 1246Y. The wild type allele N86 significantly
recovered in prevalence from 19.5% in 2003–2005 to
73.2% 2010–2012 (p < 0.0001). Although allele 184F also
increased in prevalence from 19.6% in 2003–2005 to
22.7% in 2010–2012, it was not statistically significant
(p = 0.7300). The prevalence of allele D1246 also in-
creased significantly from 74.4 to 96.7% in 2010–2012
(p < 0.0001). In 2010–2012, mixed infections were less
frequent, a 58% decrease in multiple infections was ob-
served for codon 86 and more than 80% for codons 184
and 1246 (Figure 1).
Haplotypes were compared on a two- and three-codon
basis (Table 1) and analysed for temporal prevalence
change. Minority haplotypes (<5%) and mixed infections
were excluded from the analysis. After implementation
of ACT (2010–2012), pfmdr1 haplotypes, either two-
and three-codon basis, were generally less diverse than
before the implementation of ACT (2003–2005) (Table 1).
From 2003–2005 to 2010–2012, haplotypes N86-184Y
and N86-F184 significantly increased from 12.2 to 59.4%
and 10.2 to 24.3%, respectively (p < 0.0001). On the con-
trary, 86Y-Y184 decreased from 69.4% in 2003–2005 to
16.0% in 2010–2012 (p < 0.0001) (Table 1). Comparison of
the codons combination 86–1246 showed a significant
increase of the N86-D1246 haplotype from 27.3% in
2003–2005 to 84.4% in 2010–2012 (p < 0.0001). Haplotype
86Y-D1246 of the same combination, decreased from
64.9 to 13.6% (p < 0.0001). Although the prevalence of
Figure 1 Temporal changes of prevalence at codons 86, 184 and 1246. Codons frequencies in each sample group are presented in
the inserted table (numbers in brackets represent number of samples corresponding to 2003–2005, 2010–2012 and *representing mixed
genotype infections).
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from 2003–2005 to 2010–2012 (Table 1) it did not
reach statistical significance (p = 0.7455). The three-
codon basis haplotype analysis revealed that, except for
NFD and NYD, all the other codon combination decreased
in prevalence from 2003–2005 to 2010–2012 (Table 1).
This tendency was highly significant for YYD (from 62.2
to 13.5%; p < 0.0001). Haplotypes YFY and NFY were not
detected either in 2003–2005 or 2010–2012 samples. In
2010–2012, more than half of the infections carried the
NYD, showing a significant trend of increase from 11.1 to
59.2% (p < 0.0001). The haplotype NFD (associated with
the ability to withstand higher lumefantrine concentrations)
also presented a significant increase in prevalence from
11.1% in 2003–2005 to 24.8% in 2010–2012 (p < 0.0001).
Discussion
There are signs of decreasing malaria prevalence (5.168,684
cases in 2005 and 3.381,371 cases in 2010) in Mozambique,but the disease remains a major cause of morbidity and
mortality [17,18]. Continued surveillance of molecular
markers of drug resistance and particularly, potential
markers of ACT drug tolerance are important tools for
the success of malaria control programmes.
In Mozambique, CQ was replaced by SP in combination
with AQ in 2002, followed by SP + AS in 2004 and then
SP + AS was replaced by AL as first line in 2009, because
of the high levels of SP resistance. Nevertheless, from
2004 AL has been the second line of treatment of un-
complicated malaria in the country [17,18]. In the present
study, the prevalence and temporal changes of N86Y,
Y184F and D1246Y pfmdr1 alleles were studied in Maputo
area.
The present study found a high prevalence of mutant
type 86Y and wild-type Y184 in samples from 2003–2005
(58.7 and 74.3%, respectively). This is in accordance with
other studies performed in Africa where 86Y and Y184
frequencies were also high before the introduction of
Table 1 Prevalence of Pfmdr1 haplotypes at codon N86Y,
Y184F and D1246Y in Maputo, before and after the
introduction of artemisinin-based combination therapy
Codon Haplotype 2003-2005* 2010-2012*




















*Sample collection period. Numbers in brackets represent number of samples
collectedduring the correspondent periods 2003–2005;2010–2012.
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after introduction of ACT in Mozambique was also ob-
served during two recent studies from Inhambane and
Gaza, Mozambique [19,31]. In line with this tendency,
a high prevalence of wild type N86 and D1246 and the
mutant 184Y was detected in the 2010–2012 group of
samples (Figure 1), which is again in accordance with-
other studies in Africa [3-5,16,24-31]. Overall, these
results suggest that the prevalence of 86Y and Y184
was high when SP and AQ were in use on a large-scale
basis, but when these drugs were substituted by ACT
their prevalence decreased significantly, which might
indicate that this haplotype does not confer a fitness
advantage upon ACT pressure [32].
Before ACT implementation (2003–2005) the most
common triple haplotype (pfmdr1 86,184 and 1246) was
YYD (62.2%), indicating that the previous first-line treat-
ment based in quinolines (i.e., CQ or AQ) mainly selected
pfmdr1 86Y and 184Y. The second most common haplo-
types were NYD and NFD (11.1%), indicating that N86
and D1246 were already being selected by the decreasing
use of quinolines and the introduction of AS in combin-
ation with SP. This is in line with the observations that,AS per se potentially selects for pfmdr1 N86 and D1246,
which have been associated with decreased susceptibility
to artemisinins in vitro [33,34]. Importantly however, no
such selection has been shown after monotherapy with ar-
temisinin derivatives in vivo. Another reason for the in-
creased N86 and D1246 prevalence might be that SNPs
associated with AQ resistance (86Y and 1246Y) cause a fit-
ness cost to the parasite [26], which would affect the selec-
tion pattern under different drug pressures. That is, when
quinolines pressure was released, wild type alleles (N86,
D1246) immediately begin to rise in the parasite popula-
tion. The combination of SNPs 86Y-1246Y was rare in
2010–2012 group of samples (Table 1), suggesting again
that they may be associated with a significant fitness cost
as observed previously [26].
Five to seven years after implementation of ACT in
Mozambique, a significant selection of NFD and NYD
was observed in the Maputo area. Other studies with
African-derived samples support the idea that haplotype
N86, 184F and D1246 is AL selected [3-5], while 86Y,
184Y and 1246Y is AQ or CQ selected [2,3,35-37]. Add-
itionally, a study from Thailand suggested that selection
of the haplotype N86-184F was likely caused by AS [38].
Generally, these results are consistent with a recent
study performed in samples from people living in a tour-
istic area in Inhambane, Mozambique [31] with those
from numerous studies in Africa [3-5,16,29,30,39].
Despite the challenges of validating candidate markers
of drug resistance, namely for ACT (a combination of chem-
ically unrelated molecules) [10,40-43], several works point
to pfmdr1 SNPs as possible modulators for ACT response
mainly based on the partner drug [2-5,8,23,28-31,35,42].
In the absence of definite marker for artemisinin (ART)
resistance, molecular monitoring of its partner drug
markers may contribute to predict the effectiveness of
ACT. Currently, the K13-propeller mutations (recently
proposed by Ariey and colleagues [44] as a molecular
marker for ACT resistance) may be a useful marker for
large-scale surveillance efforts to contain and prevent
global spread of ACT resistance.
Conclusion
A sustained success in malaria control is strongly dependent
on continued effectiveness of first line treatment. The re-
sults of the present work are in line with data found re-
cently in other African countries, where the wild type
allele N86 showed increased prevalence after introduction
of AL. Furthermore, it is shown a temporal increase of
184F mutant type after introduction of AL, and a signifi-
cant increase of the triple haplotype N86-184F-D1246.
Therefore, there is cause for concern/attention and close
continued surveillance of pfmdr1 SNPs, which remain
highly relevant as a marker of reduced susceptibility
to AL.
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